John Flavin

Syntax Bio's discovery platform overcomes the longstanding challenges in stem cell-derived therapies by directly controlling and accelerating cell differentiation. A shorter and more reliable cell differentiation process improves patient access by making discovery faster, less costly and scalable. Synatx’s proprietary Cellgorithm technology mimics human development using a sequential CRISPR-based system to generate a wide diversity of functional cell types to enable new product opportunities.